Agenus Competitors and Similar CompaniesClear all
Agenus's competitors and similar companies include Lyell, Halozyme Therapeutics, LogicBio Therapeutics and AstraZeneca.
 Agenus Agenus is an immuno-oncology company that focuses on the discovery and development of therapies for treating cancer. |  Halozyme Therapeutics Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment. |  LogicBio Therapeutics LogicBio Therapeutics develops lifelong cures for serious, early-onset rare diseases by combining gene therapy and gene editing in a one-time treatment. |  AstraZeneca AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines. | ||
Founding Date | Founding Date 1994 | Founding Date 2018 | Founding Date 1998 | Founding Date 2014 | Founding Date 1999 |
Type | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Lexington, US HQ Cambridge, GB Emeryville, US Berkeley, US Vacaville, US | Locations South San Francisco, US HQ Bothell, US Seattle, US | Locations San Diego, US HQ | Locations Lexington, US HQ Louisville, US | Locations Cambridge, GB HQ Alger, DZ Buenos Aires, AR Macquarie Park, AU Macquarie Park, AU North Ryde, AU Wien, AT see more |
Employees | Employees 8174% decrease | Employees 188 | Employees 373157% increase | Employees 4178% increase | Employees 94,300 |
Valuation ($) | Valuation ($) 96.2 m | Valuation ($) 243.3 m | Valuation ($) 6.4 b | Valuation ($) 176.3 m | Valuation ($) 2.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) $114.2m (FY, 2025) | Revenue (est.) $36k (FY, 2025) | Revenue (est.) $1.4b (FY, 2025) | Revenue (est.) $5.4m (FY, 2021) | Revenue (est.) $58.7b (FY, 2025) |
Cost of goods | Cost of goods $1m (FY, 2025) | Cost of goods N/A | Cost of goods $228.8m (FY, 2025) | Cost of goods N/A | Cost of goods $4.9b (FY, 2025) |
Gross profit | Gross profit $113.2m (FY, 2025) | Gross profit N/A | Gross profit $1.2b (FY, 2025) | Gross profit N/A | Gross profit $54.2b (FY, 2025) |
Net income | Net income ($3.1m) (FY, 2025) | Net income ($274.4m) (FY, 2025) | Net income $316.9m (FY, 2025) | Net income ($40m) (FY, 2021) | Net income $10.2b (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised $ 171.1m | Total funding raised N/A | Total funding raised $ 171.9m | Total funding raised $ 49m | Total funding raised $ 1b |
For sources of this data, please see the company profile
View Company Profiles
Lyell
HQ
South San Francisco, US
Employees
188
Lyell Immunopharma is a T-cell reprogramming company to cure patients with solid tumors.
View companyHalozyme Therapeutics
HQ
San Diego, US
Employees
373
Halozyme Therapeutics is a biotechnology company focused on developing and commercializing cancer therapies that target the tumor microenvironment.
View companyLogicBio Therapeutics
HQ
Lexington, US
Employees
41
LogicBio Therapeutics develops lifelong cures for serious, early-onset rare diseases by combining gene therapy and gene editing in a one-time treatment.
View companyAstraZeneca
HQ
Cambridge, GB
Employees
94,300
AstraZeneca is a biopharmaceutical company specializing in the discovery, development, manufacturing, and marketing of prescription medicines.
View company